DLL3

DLL3 Molekülinformation

Englischer Name	Delta-like protein 3	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	30	Target-Alias	Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Delta-like protein 3
Target-Alias	Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	30
Höchste Forschungs- und Entwicklungsphase	Approved

DLL3 Produktliste

Attribut
Protein (23)Cell (2)Cell Grade Beads (1)Kits (1)Beads (1)
Produktbibliothek
Online (28)
Spezies
Human (21)Cynomolgus (4)Rat (1)Rhesus macaque (1)Mouse (1)
Etikett
His Tag (17)- (6)His Tag & Avi Tag (2)Llama IgG Fc Tag (1)Fc Tag (1)Mouse IgG Fc Tag (1)
Marker
Unconjugated (16)FITC Labeled (1)Biotin-labeled (3)PE Labeled (1)- (5)APC Labeled (1)AF647 Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT AIDD‑Ready DL3-H52H4	Human	HEK293	Human DLL3 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)	In den Warenkorb legen
HOT AIDD‑Ready DL3-M52H9	Mouse	HEK293	Mouse DLL3 Protein, His Tag, low endotoxin (HPLC verified)	In den Warenkorb legen
HOT AIDD‑Ready DL3-C52H3	Cynomolgus	HEK293	Cynomolgus DLL3 Protein, His Tag (MALS verified)	In den Warenkorb legen
CEA-B049	Human	-	Human DLL3 ELISA Kit	In den Warenkorb legen
CHEK-ATP090	Human	HEK293	HEK293/Human DLL3 Stable Cell Line	In den Warenkorb legen
DL3-H5243	Human	HEK293	Human DLL3 Protein, His Tag (HPLC verified)	In den Warenkorb legen
DL3-H5259	Human	HEK293	Human DLL3 (353-465) Protein, Mouse IgG2a Fc Tag, low endotoxin	In den Warenkorb legen
DL3-H525a	Human	HEK293	Human DLL3 Protein, Llama IgG2b Fc Tag, low endotoxin	In den Warenkorb legen
DL3-H525c	Human	HEK293	Human DLL3 (27-215) Protein, Fc Tag (MALS verified)	In den Warenkorb legen
DL3-H52H3	Human	HEK293	Human DLL3 (216-310) Protein, His Tag, low endotoxin	In den Warenkorb legen

Gesamtmenge28

Produktanfrage

DLL3 Molekülhintergrund

Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.

DLL3 Molekülalias

Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Zocilurtatug pelitecan	ZL-1310; YL-212	Phase 3 Clinical	Zai Lab (Shanghai) Co Ltd	Small Cell Lung Carcinoma; Solid tumours	Details
Obrixtamig	BI-764532; OBT620	Phase 3 Clinical	C.H. Boehringer Sohn Ag & Co. Kg	Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma	Details
Alveltamig	ZG-006; ZG006	Phase 3 Clinical	Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd	Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours	Details
89Zr-DFO-SC16.56	89Zr-DFO-SC16.56	Phase 2 Clinical	Memorial Sloan Kettering Cancer Center	Small Cell Lung Carcinoma	Details
Gocatamig	HPN-328; MK-6070; DS-3280	Phase 2 Clinical	Harpoon Therapeutics	Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma	Details
EB-DART-NK01	EB-DART-NK01	Phase 2 Clinical	Beijing Biotech	Small Cell Lung Carcinoma	Details
4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute)		Phase 2 Clinical	Shenzhen Geno-Immune Medical Institute	Glioblastoma; Melanoma	Details
SHR-7787	SHR-7787; SHR7787	Phase 2 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Small Cell Lung Carcinoma; Solid tumours	Details
SHR-4849	SHR-4849; SHR4849; IDE849; IDE-849	Phase 2 Clinical	Jiangsu Hengrui Pharmaceutical Group Co Ltd	Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours	Details
DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital)	DLL3-CAR-NK cells	Phase 2 Clinical	Tianjin Medical University Cancer Institute And Hospital	Small Cell Lung Carcinoma	Details
Peluntamig	PT-217	Phase 2 Clinical	Phanes Therapeutics Inc	Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours	Details
ML-261	ML261; ML-261	Phase 1 Clinical	Moonlight Bio Inc	Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Prostatic Neoplasms; Small Cell Lung Carcinoma	Details
NEUK203-13	NEUK203-13	Phase 1 Clinical	Neukio Biotherapeutics (Shanghai) Co Ltd	Neuroendocrine Tumors; Small Cell Lung Carcinoma	Details
111In-ABD147		Phase 1 Clinical	Abdera Therapeutics Inc	Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Solid tumours	Details
111In-ETN029	111In-ETN029	Phase 1 Clinical	Novartis Pharma Ag	Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma	Details
225Ac-ETN029	225Ac-ETN029; [225Ac]Ac-ETN029	Phase 1 Clinical	Novartis Pharma Ag	Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma	Details
HLX-3901	HLX-3901	Phase 1 Clinical	Shanghai Henlius Biotech Inc	Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours	Details
177Lu-DTPA-SC16.56	177Lu-DTPA-SC16.56	Phase 1 Clinical	Memorial Sloan Kettering Cancer Center	Carcinoma, Neuroendocrine; Lung Neoplasms; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms	Details
SYS-6040	SYS6040; SYS-6040	Phase 1 Clinical	Jushi Biopharmaceutical Co Ltd	Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours	Details
IBI-3009	IBI3009; IBI-3009	Phase 1 Clinical		Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours	Details
BL-M14D1	BL-M14D1	Phase 1 Clinical	Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd	Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours	Details
BHP-01	BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T	Phase 1 Clinical	Chengdu Brilliant Pharmaceutical Co Ltd	Small Cell Lung Carcinoma	Details
FZ-AD005	FZ-AD005; FZAD005; F0041	Phase 1 Clinical	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Carcinoma, Neuroendocrine; Glioblastoma; Glioma; Small Cell Lung Carcinoma; Solid tumours	Details
[89Zr]Zr-BI-764532		Phase 1 Clinical	Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg	Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma	Details
ABD-147	ABD-147; 225Ac-ABD147	Phase 1 Clinical	Abdera Therapeutics Inc	Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours	Details
SNC-115	SNC115; SNC-115	Phase 1 Clinical	Shanghai Simnova Biotechnology Co Ltd	Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours	Details
RG-6524	RO-7616789; ALPS-12; RG6524	Phase 1 Clinical	F. Hoffmann-La Roche Ag	Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma	Details
OBT620	OBT620	Phase 1 Clinical	Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd	Small Cell Lung Carcinoma	Details
QLS-31904	QLS-31904; QLS31904	Phase 1 Clinical	Qilu Pharmaceutical Co Ltd	Solid tumours	Details
LB-2102(Legend Biotechnology)	LB-2102	Phase 1 Clinical		Neuroendocrine Tumors; Small Cell Lung Carcinoma	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Tarlatamab	AMG-757	Approved	Amgen Inc	Imdelltra	United States	Small Cell Lung Carcinoma	Amgen Inc	2024-05-16	Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details